William Blair Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

William Blair Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-482,850	Closed	-$39.1M	–	481
2018 Q1	$39.1M	Sell	482,850 -94,826	-16%	-$8.14M	0.15%	160
2017 Q4	$51.5M	Sell	577,676 -412,585	-42%	-$35.9M	0.2%	141
2017 Q3	$92.2M	Sell	990,261 -72,245	-7%	-$6.38M	0.33%	104
2017 Q2	$96.5M	Sell	1,062,506 -61,422	-5%	-$5.59M	0.35%	93
2017 Q1	$98.7M	Buy	1,123,928 +15,687	+1%	+$1.4M	0.37%	86
2016 Q4	$91.8M	Sell	1,108,241 -67,834	-6%	-$5.83M	0.37%	86
2016 Q3	$109M	Sell	1,176,075 -78,101	-6%	-$7.35M	0.41%	78
2016 Q2	$97.6M	Buy	1,254,176 +269,008	+27%	+$22.9M	0.39%	89
2016 Q1	$81.3M	Sell	985,168 -27,254	-3%	-$2.22M	0.32%	106
2015 Q4	$106M	Buy	1,012,422 +313,043	+45%	+$32.7M	0.43%	84
2015 Q3	$73.7M	Buy	+699,379	New	+$93.4M	0.15%	204

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

William Blair Investment Management's BMRN Position: Q2 2018 in Review

William Blair Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 482,850 shares — an estimated $39.1M sold.

William Blair Investment Management first reported a position in BMRN in Q3 2015 and held it in 11 quarters. The position peaked at $109M in Q3 2016. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

William Blair Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
William Blair Investment Management sold 482,850 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $39.1M.
William Blair Investment Management first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 11 quarters.
William Blair Investment Management's BioMarin Pharmaceuticals position peaked at $109M in Q3 2016.
449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on William Blair Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.